Pasithea Therapeutics (KTTA) Operating Margin (2022)

Pasithea Therapeutics recorded quarterly Operating Margin of 1679.52% in Q4 2022, up 4.78% quarter-over-quarter from 1763.76% in Q3 2022.

Pasithea Therapeutics' Operating Margin history runs 1 years deep, the most recent figure standing at 1679.52% for Q4 2022.

  • In Q4 2022, Operating Margin changed N/A year-over-year to 1679.52%; the TTM figure through Dec 2022 stood at 2654.28% (changed N/A YoY), while the FY2022 annual figure was 2587.35%, up 2733838.0% from the prior year.
  • Operating Margin came in at 1679.52% for Q4 2022 at Pasithea Therapeutics, up from 1763.76% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 1679.52% in Q4 2022 to a low of 19229.5% in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 38.10%
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 17.83%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 23.02%
10 Pasithea Therapeutics 17.41 Mn 17.41 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 -1,679.52%
Sep 30, 2022 -1,763.76%
Jun 30, 2022 -19,229.50%
Mar 31, 2022 -17,605.34%